Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20–30% of breast cancer tumours and is associated with a...
Read More...
The post HER2+ breast cancer Phase II benchmarking appeared first on Pharmaceutical Technology.
Original Article: HER2+ breast cancer Phase II benchmarking